Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 25, 2024, titled "Zydus receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg".
Press Release Jan 25 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This approval makes Zydus the first company to receive final approval for these generic tablets. The product will be manufactured at Zydus's facility in Ahmedabad and is set to launch immediately in the US market. Gabapentin is used for managing Postherpetic Neuralgia, with significant annual sales in the US market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 19 2024
- Press Release Jan 17 2024
- Press Release Dec 22 2023
- Press Release Dec 16 2023
- Press Release Dec 15 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jan 30 2024
- Press Release Feb 08 2024
- Press Release Feb 09 2024
- Press Release Feb 16 2024
- Zydus Lifesciences Limited Press Release Feb 26 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences